688799.SH
Hunan Warrant Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 43.33
−0.73%Sep 17, 2026, 09:18 UTC
Hunan Huana Pharmaceutical Investment Partnership (Limited Partnership), controlling shareholder of Huana Pharmaceutical, sold 1.38 million shares via block trade on September 17, 2026, reducing its and concert parties' combined stake from 39.09% to 38.06%.
Aug 31, 2026, 11:20 UTC
Warner Pharmaceutical received a drug registration certificate approved by the National Medical Products Administration for Loxoprofen Sodium Patch, used for anti-inflammatory and analgesic purposes, available in two specifications.
Source:Aug 24, 2026, 10:46 UTC
Hua Na Pharmaceutical increased the investment budget for its wholly-owned subsidiary Zhigen Pharmaceutical's Phase I high-end API and intermediate green manufacturing base project from no more than 650 million yuan to no more than 800 million yuan.
Source:Jul 17, 2026, 07:59 UTC
Hunan Warner Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for a supplementary application to change the marketing authorization holder of Hydroxychloroquine Sulfate Tablets.
Source: